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The Children’s Cancer Institute in Sydney recently launched an ambitious program. From 
early next year, scientists will analyse the unique cancer cells of 12 children diagnosed with 
the most aggressive forms of the disease to find the best treatment for each child.
By 2020, they aim to have these individualised treatment options available to all children 
diagnosed with cancers that have a less than 30% survival rate. This way of tailoring 
treatment to each person is known as personalised medicine, and advances in DNA 
sequencing have paved the way for a new era in cancer management.
Tailoring treatments
The modern use of the term “personalised medicine” is based on the idea that by 
understanding the specific molecular code of a person’s disease, and particularly its genetic 
makeup, we can more accurately tailor treatment to them. This approach is also referred to as 
precision medicine.
Cancer is fundamentally a disease of altered genomics – genetic material making up the 
structure of cells. Because these alterations are different in each person, every tumour is 
programmed differently with genes made up of varying sequences of DNA.
This is why not everyone will respond the same way to a 
given treatment. Determining the DNA sequence that makes 
up the genome of each tumour (genomic sequencing) helps 
doctors understand how the tumour may be effectively 
targeted.
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Understanding the DNA of tumours allows researchers to target treatment to each individual. 
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Traditionally, identifying effective cancer treatments relied on 
large clinical trials involving thousands of patients. This 
approach successfully identifies drugs effective for general 
cancer features, but these may miss the unique Achilles heel 
in some people’s cancers.
Because personalised medicine is customised treatment for 
individuals, clinical trial designs are moving from population-
based to one-person trials. Here, a person with a specific 
genomic makeup is given targeted therapies and the 
responses are tracked over time.
Genomic framework
While the Sydney children’s program has been described as the first of its kind in Australia, 
the concept of personalised medicine is not new. Cancer doctors have always managed each 
person’s cancer by using all the available information about the tumour and other pre-existing 
medical conditions.
But there are important differences in the development of personalised medicine today.
Breast cancer treatment is one example. For the last 40 years, a large factor dictating the 
clinician’s choice for breast cancer therapy was the presence or absence of oestrogen 
receptors in the tumour. Oestrogen receptors receive signals from the hormone oestrogen, 
which then generates a reaction. Without them, oestrogen wouldn’t have any affect.
If a woman’s tumour didn’t have these receptors, then doctors wouldn’t give them drugs that 
affected oestrogen as there would be no point.
But now it has become apparent that having oestrogen receptors is not the only criteria for the 
use of these drugs, as not all women who have oestrogen receptors will benefit from them.
So researchers have gone deeper to see that this is due to the different way oestrogen 
receptors function in cancer cells.
Understanding the genomic framework of the tumour can determine this function and thus 
predict the types of women who, despite having the receptor, would likely not benefit from 
such hormonal therapy.
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This understanding of a tumour’s genomic makeup has also led scientists to expand the way 
cancer is classified. Where previously we categorised cancers by their organ of origin (breast, 
pancreas etc), findings like the above mean we can now also use a genomic definition.
This has positive implications for optimising cancer treatment.
For instance, one of the most aggressive forms of breast cancer is HER2-positive cancer 
(human epidermal growth factor receptor 2). The subtype accounts for about 15% of breast 
cancers, and occurs when the tumour has extra copies of the HER2 receptor gene that 
promotes cancer cell growth.
Drugs targeting the HER2 protein have shown dramatic success in improving outcomes for 
people with this subtype. They have become standard treatment.
But it has recently been discovered that excessive HER2 is also present in about 8% of 
gastric cancers and 3% of pancreatic cancers. This means a therapy successful in one 
location has the potential to work in another, because the tumour types are similar.
Clinical trials are currently assessing whether HER2-targeted drugs can then also be effective 
against these pancreatic tumour types.
Cost and benefit
Most major cancer hospitals in Australia have trials investigating personalised medicine at 
some level. But genomic analyses aren’t widely performed on an individual patient basis.
It is likely examining each tumour in this way will become 
routine treatment in the near future. There are already 
international providers who will (for a fee) sequence tumours 
and suggest treatments based on this information.
For instance, the Foundation Medicine test profiles some 400 
known cancer driver genes and can be purchased for 
$US5,800 (approximately $A8,000). This type of test is not 
routine in Australia, but internet-savvy patients who have the 
financial means can arrange to have their tumour analysed 
with the help of their doctor.
Further to that cost of sequencing is the actual treatment, which may sometimes be an 
expensive drug not listed on the Australian Pharmaceutical Benefits Scheme for this particular 
use.
But there are advantages to the personalised approach that transcend cost.
Besides the potential of finding the right treatment, it can lead to stopping a therapy that isn’t 
working. Or result in a therapy not being undertaken at all; therapies that in many cases are 
themselves expensive and often have the added burden of side effects.
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